Synthesis and stereoselective dealkylation of N-chiral quarternary N-alkyl galanthaminium halides

Tetrahedron Asymmetry

Volumn 14, Issue 6, 2003, Pages 675-681

  Hirnschall, Manfred ^a   Treu, Matthias ^a   Mereiter, Kurt ^a   Hametner, Christian ^a   Fröhlich, Johannes ^a   Jordis, Ulrich ^a  

^a VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

11 BUTYL 4A,5,9,10,11,12 HEXAHYDRO 6 HYDROXY 3 METHOXY 11 METHYL 6H BENZOFURO[3A,3,2 EF][2]BENZAZEPINIUM IODIDE; 4A,5,9,10,11,12 HEXAHYDRO 6 HYDROXY 3 METHOXY 11 METHYL 11 (PHENYLMETHYL) 6H BENZOFURO[3A,3,2 EF][2]BENZAZEPINIUM BROMIDE; 4A,5,9,10,11,12 HEXAHYDRO 6 HYDROXY 3 METHOXY 11 METHYL 11 [4 (1,1,3 TRIOXO 2H 1,2 BENZOISOTHIAZOLYL)BUTYL] 6H BENZOFURO[3A,3,2 EF][2]BENZAZEPINIUM BROMIDE; 4A,5,9,10,11,12 HEXAHYDRO 6 HYDROXY 3 METHOXY 11 METHYL 11 [4 (1,1,3 TRIOXO 2H 1,2 BENZOISOTHIAZOLYL)BUTYL] 6H BENZOFURO[3A,3,2 EF][2]BENZAZEPINIUM IODIDE; 4A,5,9,10,11,12 HEXAHYDRO 6 HYDROXY 3 METHOXY 11,11 DIMETHYL 6H BENZOFURO[3A,3,2 EF][2]BENZAZEPINIUM IODIDE; GALANTAMINE; UNCLASSIFIED DRUG;

ARTICLE; CHIRALITY; DEALKYLATION; DIASTEREOISOMER; DRUG SYNTHESIS; PHASE TRANSITION; PRIORITY JOURNAL; SOLID STATE; STEREOCHEMISTRY; STEREOSPECIFICITY; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

EID: 0037459213     PISSN: 09574166     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0957-4166(03)00116-2     Document Type: Article

References (16)

1. Raskind M.A., Peskind E.R., Wessel T., Yuan W., Allen F.H., Aronson S.M., Baumel B., Eisner L., Brenner R., Cheren S., Verma S., Daniel D.G., DePriest M., Ferguson J.M., England D., Farmer M.V., Frey J., Flitman S.S., Harrell L.E., Holub R., Jacobson A., Olivera G.F., Ownby R.L., Jenkyn L.R., Landbloom R., Leibowitz M.T., Zolnouni P.P., Lyketosos C., Mintzer J.E., Nakra R., Pahl J.J., Potkin S.G., Richardson B.C., Richter R.W., Rymer M.M., Saur D.P., Daffner K.R., Scinto L., Stoukides J., Targum S.D., Thein S.G., Thien S.G., Tomlinson J.R. Neurology. 54:2000;2261-2268.
2. Bores G.M., Kosley R.W. Drugs Future. 21:1996;621-635.
3. Lilienfeld S. CNS Drug Rev. 8:2002;159-176.
4. Carroll P., Furst G.T., Han S.Y., Joullie M. Bull. Soc. Chim. Fr. 1990;769-780.
5. Matusch R., Kreh M., Mueller U. Helv. Chim. Acta. 77:1994;1611-1615.
6. Cooke M.P., Parlman R.M. J. Org. Chem. 40:1975;531-532.
7. Fellows I., Carr R.M., DeBoeck N., Montgomery S., Waterhouse I., Sutherland D.R. J. Labelled Compd. Radiopharm. 41:1998;1127-1243.
8. Fleischhacker W., Richter B. Chem. Ber. 112:1979;2539-2551.
9. Manoharan T.S., Madyastha M.K., Bali Singh B., Bhatnagar S.P., Weiss U. Synthesis. 10:1983;809-812.
10. Stichting Biomedical Research and Advice Group, NL Patent 8 800 350,1989; Chem. Abstr. 1989, 112, 112096.
11. Jordis, U.; Fröhlich, J.; Treu, M.; Hirnschall, M.; Czollner, L.; Kaelz, B.; Welzig, S. WO 0 174 820, 2001; Chem. Abstr. 2001, 135, 304054.
12. Han S.Y., Sweeney J.E., Bachman E.S., Schweiger E.J., Forloni G., Coyle J.T., Davis B.M., Joullie M.M. Eur. J. Med. Chem. 27:1992;673-687.
13. Bruker AXS: Programs SMART, version 5.054; SAINT, version 6.2.9; SADABS version 2.03; XPREP, version 5.1; SHELXTL, version 5.1. Bruker AXS Inc., Madison, WI, USA, 2001.
14. Sheldrick, G. M. SHELX97. Program system for crystal structure determination. University of Göttingen, Germany, 1997.
15. CCDC 187697, 187698 and 187699 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033; e-mail: deposit@ccdc.cam.ac.uk).
16. For structural data of galanthamine type compounds see Cambridge Crystallographic Database entries GALAMI, GALANT, HICRAM, NRGLNM, RIWKOX, SIBHAM, VATMEI, VATMIM, and YILTUI (database version of April, 2002), and references cited therein.